Dr. Fakhri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94304Phone+1 650-723-4000
Summary
- Dr. Bita Fakhri is an oncologist in San Francisco, CA and is affiliated with UCSF Medical Center. She received her medical degree from Iran University of Medical Sciences and has been in practice 8 years. She also speaks multiple languages, including Farsi. She specializes in hematologic oncology.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2015 - 2018
Boston University Medical CenterResidency, Internal Medicine, 2012 - 2015
Yale School of Public HealthMPH, Epidemiology, 2010 - 2011
Iran University of Medical SciencesClass of 2009
Certifications & Licensure
CA State Medical License 2017 - 2025
MO State Medical License 2016 - 2019
MA State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2018 Nov 16
- Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation Start of enrollment: 2019 May 07
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2020 Dec 03
Publications & Presentations
PubMed
- 233 citationsPirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Yoon Cheah, John M. Pagel
Lancet. 2021-03-06 - 41 citationsLisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie
Lancet. 2023-08-19 - 86 citationsNCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson
Journal of the National Comprehensive Cancer Network. 2021-11-01
Abstracts/Posters
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesBita Fakhri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin LymphomaBita Fakhri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Dr. Fakhri on Ongoing Clinical Trials in CLLFebruary 17th, 2020- Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLLJanuary 24th, 2020
- Advances Continue at Rapid Pace in CLL ParadigmJanuary 21st, 2020
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
